Peptides for Energy and Fatigue: What the Research Explores

If you spend any time in biohacking forums, you will eventually run into peptides for energy and fatigue: a small cluster of mitochondrial compounds that promise to work at the level of the cell's own power plants. The pitch is seductive because it sounds mechanistic rather than magical. Target the mitochondria, the story goes, and the tiredness takes care of itself. The reality is more interesting, and more honest, than that. Most of what we know comes from cell studies and animal work, with only a handful of human trials, and the one large human fatigue trial in this space did not land where its backers hoped. This guide maps the category in plain English: what MOTS-c, SS-31, and NAD+ actually are, what researchers have measured, and where the evidence quietly runs out.

What "peptides for energy and fatigue" actually means

The phrase peptides for energy and fatigue is really shorthand for a small family of molecules that act on mitochondria, the organelles that turn food and oxygen into ATP, the cell's usable energy currency. The logic behind the category is a genuine scientific hypothesis: because low cellular energy output is a feature of aging and of several diseases, compounds that support mitochondrial function might, in theory, affect how energetic a person feels. Two of the best-studied candidates, MOTS-c and SS-31, are true peptides, short chains of amino acids. A third, NAD+, is a coenzyme rather than a peptide, but it sits in the same conversation because it is central to the same energy-producing reactions. It is worth being clear up front that a plausible mechanism is not the same as a proven benefit, and most of this field is still at the mechanism stage.

MOTS-c: a mitochondrial peptide tied to exercise

MOTS-c is the compound that put this category on the map. Discovered in 2015, it is a 16-amino-acid peptide encoded inside the mitochondrial genome itself, in a region of the 12S ribosomal RNA. In mouse studies, MOTS-c was shown to activate AMPK, a master metabolic switch, and to regulate insulin sensitivity and metabolic homeostasis, with skeletal muscle as its main target. A later study added the detail that most excites the biohacking crowd: exercise raises the body's own MOTS-c in human muscle and blood, and giving MOTS-c to mice was associated with improved running capacity in young, middle-aged, and old animals. That is a striking set of findings, but note the register. The performance results are from mice, and the human data so far shows only that MOTS-c moves with exercise, not that taking it changes how people feel. We cover the specifics on our MOTS-c page.

SS-31 (elamipretide): aimed at the mitochondrial membrane

SS-31, also known as elamipretide, takes a different approach. It is a small tetrapeptide designed to concentrate inside the inner mitochondrial membrane, where it binds a lipid called cardiolipin. In laboratory and animal studies, that binding was associated with better-protected electron transport and faster ATP recovery in mitochondria that had been stressed by loss of blood flow. On paper, this is exactly the kind of mechanism the energy-and-fatigue story wants. But SS-31 is also where the category runs into its most important reality check. In MMPOWER-3, a phase-3 randomized controlled trial in adults with primary mitochondrial myopathy, elamipretide did not meet its two primary endpoints, walking distance and a total fatigue score, versus placebo. In other words, the single largest human trial in this space that was designed partly around fatigue came back negative. You can read our fuller breakdown on the SS-31 page.

NAD+ and the age-related energy decline

NAD+ (nicotinamide adenine dinucleotide) is the coenzyme that most of the mitochondrial reactions actually run on, which is why it keeps appearing in energy-and-fatigue discussions even though it is not a peptide. A major review describes NAD+ as central to energy metabolism and documents that its levels gradually decline with age across tissues, a decline linked to several age-related conditions. That has driven interest in raising NAD+ with precursors such as nicotinamide riboside. Here the human evidence is a little further along: in a randomized, placebo-controlled crossover trial, chronic nicotinamide riboside was well-tolerated and raised NAD+ levels in healthy middle-aged and older adults. What that trial did not do is demonstrate more energy or less fatigue; it measured the biochemistry, not the subjective feeling. NAD+ itself is broken down in the gut, so most products aim at precursors instead, and our NAD+ page walks through those distinctions.

What the research does and does not show

Step back and a consistent pattern emerges. The mechanisms are real and, in places, elegant: MOTS-c genuinely acts on AMPK, SS-31 genuinely binds cardiolipin, and NAD+ genuinely fuels mitochondrial metabolism. What is missing is the bridge from mechanism to a reliable, measurable effect on energy or fatigue in people. The mouse performance data for MOTS-c has not been reproduced as a human outcome, the one large human fatigue trial for elamipretide was negative, and the NAD+ precursor trials so far confirm the biochemistry without confirming the felt benefit. No controlled human study establishes any of these compounds as a way to relieve everyday tiredness, and none has been tested in people with chronic fatigue. Anyone claiming otherwise is running ahead of the evidence.

Benefits, trade-offs, and side effects to weigh

So what should a curious reader take away? On the benefit side, these are among the few compounds whose energy claims rest on a named, plausible mitochondrial mechanism rather than pure marketing, and MOTS-c and NAD+ precursors have early human data that at least points somewhere. On the trade-off side, the human efficacy evidence for a felt energy or fatigue benefit is thin to absent, the standout human trial was negative, and long-term safety in healthy people is largely uncharacterized. Reported and theoretical downsides range from injection-site reactions and gastrointestinal upset to simply spending money on an effect that may never materialize. There is also a supply problem that has nothing to do with biology: independent testing of products sold online without a prescription has repeatedly found material with purity far below the label and bacterial endotoxin in every sample tested. For a research chemical handled outside any pharmacy, that contamination is not a footnote.

The research-grade reality

One more distinction matters more than any mechanism. The MOTS-c, SS-31, and NAD+ products sold through peptide vendors are research-grade chemicals labeled for laboratory use only, not for human consumption. They are not FDA-approved for energy, fatigue, or any other human use, and elamipretide, the most clinically advanced of the group, remains investigational rather than an available medicine. We deliberately keep specific how-to-use details off the page, because that crosses from education into telling people how to run an experimental chemical on themselves. If you are researching this category, treat a vendor's third-party purity and certificate-of-analysis testing as the first question, not the last.

The honest bottom line

Peptides for energy and fatigue are one of the more scientifically grounded corners of the biohacking world, and also one of the most over-promised. MOTS-c, SS-31, and NAD+ each act on a real mitochondrial mechanism, and a few early human studies are genuinely intriguing, but no controlled trial yet shows that any of them makes a healthy person feel more energetic or less tired, and the biggest human fatigue trial in the group came back negative. If you want the compound-by-compound detail, start with our MOTS-c, SS-31, and NAD+ pages, and read them the way we wrote them: mechanism first, honest about the gaps, and clear that these remain research chemicals rather than proven answers to fatigue.

References & sources

1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3).
2. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021;12.
3. Birk AV, Liu S, Soong Y, et al. The mitochondrial-targeted compound SS-31 re-energizes ischemic mitochondria by interacting with cardiolipin. Journal of the American Society of Nephrology. 2013;24(8).
4. Karaa A, Bertini E, Carelli V, et al. Efficacy and safety of elamipretide in individuals with primary mitochondrial myopathy: the MMPOWER-3 randomized clinical trial. Neurology. 2023.
5. Covarrubias AJ, Perrone R, Grozio A, et al. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021;22:119-141.
6. Martens CR, Denman BA, Mazzo MR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9:1286.
7. Ashraf AR, Mackey TK, Vida RG, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription: market surveillance, content analysis, and product purchase evaluation study. Journal of Medical Internet Research. 2024.